Targeting degradation pathways is a promising approach in cancer therapy. Drugs that inhibit the proteasome, such as bortezomib, have been effective in treating multiple myeloma by preventing the degradation of pro-apoptotic factors, thereby inducing cell death in cancer cells. Additionally, novel therapies aim to harness the body's own degradation machinery to eliminate cancerous proteins selectively.
